- (a) Identification. A tympanic membrane contact hearing aid is a prescription wearable device that compensates for impaired hearing. Amplified sound is transmitted by vibrating the tympanic membrane through a transducer that is in direct contact with the tympanic membrane. A tympanic membrane contact hearing aid is subject to the requirements in § 801.422 of this chapter.
(b) Classification. Class II (special controls). The special controls for this device are:
- (1) The patient contacting components must be demonstrated to be biocompatible.
(2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, and must include:
- (i) Mechanical integrity testing;
- (ii) Electrical and thermal safety testing;
- (iii) Software verification, validation, and hazard analysis;
- (iv) Reliability testing consistent with expected device life;
- (v) Electromagnetic compatibility testing; and
- (vi) Validation testing of device output and mechanical force applied to the tympanic membrane in a clinically appropriate model.
- (3) Clinical performance testing must characterize any adverse events observed during clinical use, and demonstrate that the device performs as intended under anticipated conditions of use.
- (4) Professional training must include the ear impression procedure, correct placement, fitting, monitoring, care, and maintenance of the device.
(5) Labeling must include the following:
- (i) A detailed summary of the adverse events and effectiveness outcomes from the clinical performance testing;
- (ii) Detailed instructions on how to fit the device to the patient;
- (iii) Instructions for periodic cleaning of any reusable components;
- (iv) Information related to electromagnetic compatibility; and
(v) Patient labeling that includes:
- (A) A patient card that identifies if a patient has been fitted with any non-self- removable components of the device and provides relevant information in cases of emergency;
- (B) Information on how to correctly use and maintain the device;
- (C) The potential risks and benefits associated with the use of the device; and
- (D) Alternative treatments.
[81 FR 3326, Jan. 21, 2015, as amended at 87 FR 50762, Aug. 17, 2022]